Immunoglobulin class‐switch recombination: Mechanism, regulation, and related diseases
MedComm · 2024-08 · 5 (8)
DOI: 10.1002/mco2.662 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 13.08.2024. Verfasst von Jia-Chen Liu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 203 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Maturation of the secondary antibody repertoire requires class‐switch recombination (CSR), which switches IgM to other immunoglobulins (Igs), and somatic hypermutation, which promotes the production of high‐affinity antibodies. Following immune response or infection within the body, activation of T cell‐dependent and T cell‐independent antigens triggers the activation of activation‐induced cytidine deaminase, initiating the CSR process. CSR has the capacity to modify the functional properties of antibodies, thereby contributing to the adaptive immune response in the organism. Ig CSR defects, characterized by an abnormal relative frequency of Ig isotypes, represent a rare form of primary immunodeficiency. Elucidating the molecular basis of Ig diversification is essential for a better understanding of diseases related to Ig CSR defects and could provide clues for clinical diagnosis and therapeutic approaches. Here, we review the most recent insights on the diversification of five Ig isotypes and choose several classic diseases, including hyper‐IgM syndrome, Waldenström macroglobulinemia, hyper‐IgD syndrome, selective IgA deficiency, hyper‐IgE syndrome, multiple myeloma, and Burkitt lymphoma, to illustrate the mechanism of Ig CSR deficiency. The investigation into the underlying mechanism of Ig CSR holds significant potential for the advancement of increasingly precise diagnostic and therapeutic approaches.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China.
- Department of Pathogen Biology School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology…
- Department of Respiratory The First Affiliated Hospital of Yangtze University Jingzhou China.
- Department of Immunology Mayo Clinic College of Medicine and Science Rochester USA.
- Laboratory for Cytokine Regulation, Center for Integrative Medical Science (IMS), RIKEN Yokohama Institute Yokohama Japan.
- Department of Paediatrics and Adolescent Medicine LKS Faculty of Medicine The University of Hong Kong Hong Kong China.
ORCID-Profile: Chao-Hong Liu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, J. C., Zhang, K., Zhang, X., Guan, F., Zeng, H., Kubo, M., Lee, P., Candotti, F., James, L. K., Camara, N. O. S., Benlagha, K., Lei, J. H., Forsman, H., Yang, L., Xiao, W., Liu, Z., & Liu, C. H. (2024). Immunoglobulin class‐switch recombination: Mechanism, regulation, and related diseases. MedComm, 5(8). https://doi.org/10.1002/mco2.662
Vancouver
Liu JC, Zhang K, Zhang X, Guan F, Zeng H, Kubo M, et al. Immunoglobulin class‐switch recombination: Mechanism, regulation, and related diseases. MedComm. 2024;5(8). doi:10.1002/mco2.662
BibTeX
@article{Liu2024,
author = {Liu, Jia-Chen and Zhang, Ke and Zhang, Xu and Guan, Fei and Zeng, Hu and Kubo, Masato and Lee, Pamela and Candotti, Fabio and James, Louisa Katherine and Camara, Niels Olsen Saraiva and Benlagha, Kamel and Lei, Jia-Hui and Forsman, Huamei and Yang, Lu and Xiao, Wei and Liu, Zheng and Liu, Chao-Hong},
title = {Immunoglobulin class‐switch recombination: Mechanism, regulation, and related diseases},
journal = {MedComm},
year = {2024},
volume = {5},
number = {8},
doi = {10.1002/mco2.662}
}
EUVIMED